AktiVax

About:

AktiVaxTM develops novel reconstitution and safety syringes for vaccines and biologics.                           

Website: http://www.aktivax.com

Description:

AktiVaxTM is creating a paradigm shift in vaccine delivery that will solve vaccine partners’ problems, costs, and complexities by providing an alternative to the traditional syringe and vial system. AktiVax’s solution involves a three-pillared approach: expertise in cost-effective, dry vaccine formulation; differentiated delivery devices; and efficient manufacturing for rapid market distribution. Our proposition has already attracted a number of vaccine partners representing a significant portion of the $30 billion vaccine industry. We believe that our solution will create a new standard of care in the vaccine market.

Total Funding Amount:

$515000

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Aurora, Colorado, United States

Founded Date:

2008-01-01

Contact Email:

info(AT)aktivax.com

Founders:

Amir Genosar

Number of Employees:

1-10

Last Funding Date:

2012-03-21

IPO Status:

Private

Industries:

© 2025 bioDAO.ai